Scholarlink

Background <p>Limb ulcers are common in hemodialysis (HD) and often have a poor prognosis despite standard care. Rheopheresis is a plasmapheresis technique that reduces blood viscosity and erythrocyte aggregation and has been proposed as an adjunctive therapy, but no study has yet compared it to standard care alone.</p> Methods <p>We conducted a retrospective multicenter study comparing 61 hemodialysis (HD) patients treated with rheopheresis for limb ulcer or amputation in five French dialysis centers with 119 HD patients receiving standard care matched on age, lesion type, and lesion site. Outcomes were analyzed using propensity score–matched cohorts. The primary outcome was 1-year amputation-free survival (AFS).</p> Results <p>One-year AFS reached 58.9% (95% CI: 45.1; 70.4) in the rheopheresis cohort and 28.8% (95% CI: 20.9; 37.2) in the standard care cohort. This difference did not reach statistical significance after adjustment for immortal-time bias (HR: 1.28, 95% CI: 0.72–2.25). Secondary outcomes followed similar trends, slightly in favor of rheopheresis without reaching significance. Major adverse events occurred in only 2.4% of rheopheresis sessions, and no treatment-related deaths were reported.</p> Conclusions <p>Rheopheresis was well tolerated and demonstrated a favorable safety profile. Clinical outcomes were numerically better with rheopheresis compared to standard care, although differences did not reach statistical significance. These findings suggest a potential benefit, warranting larger prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rheopheresis in hemodialysis patients with limb ulcers or amputation: safety and outcomes from a multicenter cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Yuri Bonsante,
  • Cyril Ferdynus,
  • Ehshaneraza Asgarali,
  • Ludovic Di Ascia,
  • Henri Vacher-Coponat,
  • Asma Allal,
  • Anabelle Baillet,
  • Gabriel Gruget,
  • Stéphanie Delelis,
  • Reuben Veerapen,
  • Julien Gayon,
  • Hamza Naciri Bennani,
  • Arnaud Le Flecher

摘要

Background

Limb ulcers are common in hemodialysis (HD) and often have a poor prognosis despite standard care. Rheopheresis is a plasmapheresis technique that reduces blood viscosity and erythrocyte aggregation and has been proposed as an adjunctive therapy, but no study has yet compared it to standard care alone.

Methods

We conducted a retrospective multicenter study comparing 61 hemodialysis (HD) patients treated with rheopheresis for limb ulcer or amputation in five French dialysis centers with 119 HD patients receiving standard care matched on age, lesion type, and lesion site. Outcomes were analyzed using propensity score–matched cohorts. The primary outcome was 1-year amputation-free survival (AFS).

Results

One-year AFS reached 58.9% (95% CI: 45.1; 70.4) in the rheopheresis cohort and 28.8% (95% CI: 20.9; 37.2) in the standard care cohort. This difference did not reach statistical significance after adjustment for immortal-time bias (HR: 1.28, 95% CI: 0.72–2.25). Secondary outcomes followed similar trends, slightly in favor of rheopheresis without reaching significance. Major adverse events occurred in only 2.4% of rheopheresis sessions, and no treatment-related deaths were reported.

Conclusions

Rheopheresis was well tolerated and demonstrated a favorable safety profile. Clinical outcomes were numerically better with rheopheresis compared to standard care, although differences did not reach statistical significance. These findings suggest a potential benefit, warranting larger prospective studies.